Founded 2015
Founders Nael Kassar


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 25
Average round size
The average size of a deal this fund participated in
Portfolio companies 19
Rounds per year 4.17
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 4
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Medical Device
  • Medical
  • Biotechnology
  • Therapeutics

The venture was found in North America in United States. The main department of described VC is located in the New York.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the KCK, startups are often financed by Venrock, Piton Capital, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Exor Seeds, Venrock. In the next rounds fund is usually obtained by Sofinnova Partners, S-Cubed Capital, Kleiner Perkins.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Education, Financial Services. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Earlens Corporation, Affirmed Networks, Wunder Mobility.

The fund was created by Nael Kassar. The overall number of key employees were 4.

Speaking about the real fund results, this VC is 38 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2014. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this KCK works on 24 percentage points less the average amount of lead investments. The typical startup value when the investment from KCK is 100-500 millions dollars. The fund is constantly included in 2-6 deals per year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of KCK:
Typical Co-investors
KCK is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after KCK:

Funds with similar focus

Funds from United States, New York
Funds with similar focus located in United States, New York:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
EastWest VentureGroup United States, Los Angeles
International Biotechnology Trust United Kingdom, London
Danisco A/S Denmark, Copenhagen
Daegyo Investment -
Accelerator Life Science Partners -
Jiangxing Shiye China, Futian
Southern Raytai Group -
Jiesi Hanneng China, Huangpu
Larastone Holding GmbH -
Shenzhen Riwei Investment China, Shenzhen

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Mainspring Energy

Clean Energy
Oil and Gas
$95M04 May 2021 United States, " United States"}

Mainstay Medical

Emergency Medicine
Health Care
Medical Device
$108M16 Feb 2021 Ireland, Dublin


Health Care
Medical Device
Monitoring Equipment
Therapeutic Devices
$33M31 Aug 2020 United States, Mountain View

Aerin Medical

Health Care
Medical Device
$48M17 Aug 2020 United States, Sunnyvale

Autobahn Labs

Life Science
24 Jun 2020 United States, Palo Alto

RefleXion Medical

Health Care
Medical Device
$100M17 Apr 2020 United States, Hayward

Wunder Mobility

Car Sharing
Electric Vehicle
Fleet Management
Ride Sharing
$30M19 Sep 2019 Germany, Hamburg

Sight Sciences

Health Care
Health Diagnostics
$31M04 Sep 2019 United States, " United States"}

Real Estate
$50M03 Feb 2019 United Arab Emirates, " United Arab Emirates"}
Crusoe Closes $128M Series B

– Crusoe Energy Systems from San Francisco has closed a $128m Series B equity financing led by Valor Equity Partners.
Lowercarbon Capital, DRW Venture Capital, Founders Fund, Bain Capital Ventures, Coinbase Ventures, Polychain Capital, KCK Group, Upper90, Winklevoss Capital, Exor, Zigg Capital and JB Straubel participated.
– The company provides solutions for the energy industry.

Mainstay Medical Receives US$108M Equity Financing

– Mainstay Medical Holdings, a Dublin, Ireland-based medical device company focused on commercializing an innovative implantable restorative neurostimulation system for people with disabling mechanical Chronic Low Back Pain, closed an equity financing of US$108m.
– The round was co-led by new investors Ally Bridge Group and Sofinnova Partners, through its Crossover Fund, and also included a large, global medical device company.
– Key existing investors participating include Sofinnova Partners (Capital Fund), KCK Group and Fountain Healthcare Partners.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent KCK?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: